Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Non-randomized Study of a Atezolizumab (MPDL3280A) in Combination With Carboplatin Plus Pemetrexed in Patients Who Are Chemotherapy-naive and Have Stage IV Non-squamous Non-small Cell Lung Cancer Twith Asymptomatic Brain Metastasis

Trial Profile

Phase II Non-randomized Study of a Atezolizumab (MPDL3280A) in Combination With Carboplatin Plus Pemetrexed in Patients Who Are Chemotherapy-naive and Have Stage IV Non-squamous Non-small Cell Lung Cancer Twith Asymptomatic Brain Metastasis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2018

At a glance

  • Drugs Atezolizumab (Primary) ; Carboplatin (Primary) ; Pemetrexed (Primary) ; Dexamethasone; Folic acid; Vitamin B12 analogues
  • Indications Brain metastases; Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ATEZO-BRAIN
  • Most Recent Events

    • 08 Aug 2018 Planned primary completion date changed from 15 Jun 2021 to 15 Jul 2021.
    • 08 Aug 2018 Status changed from not yet recruiting to recruiting.
    • 18 May 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top